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Summary
Anatomical and functional studies of central relaxin-3/RXFP3 systems suggest they constitute 
an ascending arousal network. For example, relaxin-3 knockout mice display circadian hypo-
activity compared to wild type littermate controls. In studies to explore the effect of chronic 
RXFP3 activation on behaviour, we engineered a lentiviral construct to constitutively secrete 
the RXFP3 agonist, R3/I5, and express a green fluorescent protein (GFP) marker in transduced 
cells. Intracerebroventricular injection of the lenti-R3/I5-GFP virus (~10^8 genomic copies in 2 
µl) in adult C57BL/6J mice resulted in GFP expression within cells of the ventricle walls and 
choroid plexus over a period of 1-4 weeks, suggesting likely chronic R3/I5 secretion and RXFP3 
activation in brain regions proximal to the ventricular system. Subsequent testing in automated 
locomotor cells on day 8 and 9 post-injection revealed that lenti-R3/I5-GFP treated mice dis-
played prolonged, elevated locomotor activity (~18% higher over the last 15 min on day 8, and 
over the entire 30 min test on day 9) compared to mice injected with a control lenti-GFP virus, 
which habituated normally to the novel environment (n=18/12 respectively, p<0.05). These 
findings are consistent with an earlier report of increased activity scores in rats acutely injected 
centrally with R3/I5, and further suggest a role for relaxin-3/RXFP3 signalling in promoting 
behavioural arousal.
Key words
Relaxin-3, RXFP3, R3/I5, lentivirus, arousal, locomotor activity
Introduction
Relaxin-3 is an abundant brain neuropeptide that binds and activates the Gi/o-pro-
tein coupled receptor, RXFP3 (Liu et al., 2003; Ma et al., 2007), and existing anatom-
ical and functional evidence suggests relaxin-3/RXFP3 signalling modulates behav-
ioural state and arousal (Smith et al., 2011). Arousal is broadly associated with a 
range of states including wakefulness, attention and vigilance; and influences modal-
ities such as motivation, spatial navigation, and learning and memory. Relaxin-3/
RXFP3 networks likely act via interactions with other circuits that play a role in pro-
moting arousal. For example, high densities of relaxin-3 fibres and RXFP3 binding 
sites are present throughout the septohippocampal system (Ma et al., 2007; Smith et 
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al., 2010), which strongly modulates hippocampal oscillatory activity, with increased 
theta rhythm considered the ‘on’ state of the hippocampus and functionally associ-
ated with exploratory behaviour (Vertes et al., 2004). Furthermore, relaxin-3 fibres/
terminals and RXFP3 are abundant within the limbic system, which provides a major 
input to the hypothalamus and the mesolimbic dopaminergic pathway which are 
both important for motivation and reward drive; and there is accumulating function-
al evidence suggesting that relaxin-3/RXFP3 signalling can act on these processes, 
particularly feeding behaviour (Ganella et al., 2012, 2013). 
The aim of the present study was to further explore the role of relaxin-3/RXFP3 
signalling in behavioural arousal by assessing the effect of chronic activation of 
RXFP3 in mice by the selective RXFP3 agonist R3/I5 (Liu et al., 2005). Traditional 
methods of chronic peptide delivery, such as repeated injections or surgical implan-
tation of a minipump and an indwelling brain cannula, have some disadvantages. 
For example, large quantities of peptides are required, and an indwelling minipump 
and cannula can be cumbersome and impede behaviour, while repeated handling for 
injections can obscure chronic behavioural changes. We recently developed an ade-
no-associated viral construct (AAV-FIB-R3/I5) that constitutively secretes the relax-
in-3 agonist R3/I5 from transduced neurons, and which we demonstrated was effec-
tive in chronically modulating RXFP3 function in rat hypothalamus (Ganella et al, 
2013). In this study we have cloned the FIB-R3/I5 coding region into lentivirus (‘len-
ti-R3/I5-GFP’) to enable the transduction of multiple cell types after central injection. 
Importantly, lentivirus injection into the lateral cerebral ventricle has been shown to 
transduce cells in the ventricle wall and choroid plexus, resulting in secretion of gene 
product into the cerebrospinal fluid and subsequent predictable biological actions 
(Regev et al., 2009). 
Methods
Viral constructs: The lenti-R3/I5-GFP construct consisted of (in 5′ to 3′ order): 
cytomegalovirus (CMV) promoter; FIB-R3/I5 coding region (FIB, fibronectin secreto-
ry sequence to ensure R3/I5 is secreted rather than retained in the cytoplasm; R3/
I5, sequence encoding pro-R3/I5); internal ribosome entry site (IRES), and; sequence 
encoding GFP. The lenti-GFP construct consisted of a CMV promoter and the GFP 
sequence. Mice and surgery: Adult male C57BL/6J mice were anaesthetised and stereo-
taxically injected with approximately 10^8 virulent particles in 2 µl of either lenti-R3/
I5-GFP or lenti-GFP (control) virus. Automated locomotor cell: On two consecutive days 
at 8 and 9 days post-surgery, mice were placed in automated locomotor cells (approx 
40 × 40 cm) under low lighting for 30 min during the light phase. Histology: Brains 
were harvested following transcardial perfusion, and 40 µm sections were cut on a 
cryostat and mounted before imaging via fluorescence microscopy.
Results
Following intracerebroventricular (icv) injection of lenti-R3/I5-GFP or lenti-GFP 
virus, GFP-positive cells were observed within the ventricle wall and choroid plex-
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us 1-4 weeks post-injection (Fig. 1A,B; two week time point shown). Testing in auto-
mated locomotor cells on day 8 and 9 post-injection revealed that lenti-R3/I5-GFP 
virus-treated mice displayed prolonged, high levels of activity (i.e. reduced habitua-
tion) over the last 15 min on day 8, and over the entire 30 min on day 9, that was on 
Figure 1. 1-4 weeks after icv infusion of the lenti-R3/I5-GFP virus in mice, transduced GFP-positive cells were 
observed within the ventricle wall (A) and choroid plexus (B) (two week time point is shown), indicating R3/
I5 secretion into the cerebrospinal fluid over this time period. (C) Distance travelled in automated locomotor 
cells (30 min) by mice tested 8 and 9 days after infusion of either lenti-R3/I5-GFP or lenti-GFP virus. Abbre-
viations: 4V, 4th ventricle; CP, choroid plexus; Fi, fimbra of hippocampus; LV, lateral ventricle; Pr, prepositus 
nucleus. Scale bar = 300 µm. Data are expressed as mean ± SEM. * p<0.05, two-way RM ANOVA, main effect 
of treatment.
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average 18% greater than the distance travelled by mice treated with the lenti-GFP 
control virus (two-way RM ANOVA, main effect of treatment, p<0.05; treatment × 
time interaction, p>0.05) (Fig. 1C).
Discussion and Conclusion
These initial studies demonstrate the likely utility of the lenti-R3/I5-GFP virus to 
chronically deliver R3/I5 into the brain of adult mice. This follows the successful use 
of the FIB-R3/I5 construct driven by AAV transduction in neurons of the rat brain 
to chronically modulate feeding (Ganella et al., 2013). Viral driven R3/I5 production 
therefore yields effective long term modulation of behaviour, although we are not yet 
able to directly measure R3/I5 levels in cerebrospinal fluid or brain, and hence it is 
difficult to determine dose-related effects. Nonetheless, the presence of a difference 
in the behaviour of mice injected with lenti-R3/I5-GFP virus compared to lenti-GFP 
controls suggests sufficient R3/I5 is present within the brain to activate RXFP3 within 
functionally relevant circuits.
The ability of chronic R3/I5 to reduce habituation to a novel environment and 
maintain higher locomotor activity during the test period is in line with previous 
studies of relaxin-3/RXFP3 function. For example, relaxin-3 knockout mice display 
circadian hypoactivity on running wheels compared to wildtype controls (Smith et 
al., 2012), and acute central infusion of R3/I5 in rats was reported to increase total 
activity in locomotor cells (Sutton et al., 2009) – an effect similar to that observed 
here. Furthermore, local infusion of a specific RXFP3 agonist into the rat medial sep-
tum was shown to promote hippocampal theta rhythm (Ma et al., 2009).
Intra-hypothalamic injection of AAV-FIB-R3/I5 was recently shown by our labora-
tory to increase bodyweight in rats (Ganella et al., 2013). A similar effect was absent 
in the present study (data not shown), which utilized a different experimental species 
(see Smith et al., this volume), injection site and virus/construct. Despite these differ-
ences, however, AAV-FIB-R3/I5-treated rats displayed a trend for increased activity 
compared to controls during their second session in automated locomotor cells, an 
effect in line with the reduced habituation observed in lenti-R3/I5-GFP-treated mice, 
which may reflect the modulation of homologous arousal-related circuits by R3/I5 in 
both studies.
In conclusion, the present study describes further evidence that relaxin-3/RXFP3 
signalling acts to promote behavioural arousal in mice and provides an initial evalua-
tion of the effectiveness of a new viral-based method to explore this emerging neuro-
peptide/GPCR system.
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